CN102488684A - Application of sumatriptan in preparation of medicines for preventing and treating narcomania - Google Patents
Application of sumatriptan in preparation of medicines for preventing and treating narcomania Download PDFInfo
- Publication number
- CN102488684A CN102488684A CN2011104572843A CN201110457284A CN102488684A CN 102488684 A CN102488684 A CN 102488684A CN 2011104572843 A CN2011104572843 A CN 2011104572843A CN 201110457284 A CN201110457284 A CN 201110457284A CN 102488684 A CN102488684 A CN 102488684A
- Authority
- CN
- China
- Prior art keywords
- sumatriptan
- preparation
- preventing
- medicines
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a novel application of sumatriptan or its pharmaceutically acceptable salt in preparation of medicines for preventing and treating opioid dependence symptoms. The invention also provides a novel application of a preparation containing sumatriptan or its pharmaceutically acceptable salt in preparation of medicines for preventing and treating opioid dependence symptoms. Compared with the current medicines for preventing and treating opioid dependence symptoms, the sumatriptan has the advantages of definite therapeutic effect as well as small toxic and side effect, and can be an ideal drug rehabilitation medicine for administration.
Description
Technical field
The present invention relates to anti-additive medicament, sumatriptan or its pharmaceutically acceptable salt application in the medicine of preparation prevention or treatment opioid dependent symptoms of more specifically saying so.
Background technology
At present, it is all very big to social security and human health damage to take drugs, and in worldwide, is listed as serious social effects of pollution with environmental pollution, climate warming.Because the addiction property after drugs are sucked makes the smoker be difficult to give up.At present the detoxification medicine can be divided into substantially: a little less than addicted opioid receptor agonist, like methadone etc.; The opiate receptor blocker is like naltrexone etc.; The non-opium medicine is like α-2 norepinephrine receptor agonist clonidine or lofexidine etc.; M nachr antagonist scopolamine and Anisodamine etc.; Chinese medicine preparation.These medicines truly have certain drug abstinence, but because drug user's psychic dependence is high, and also there is certain addiction property in alternative medicine itself, it is high that junkie is given up the back relapse rate; Though Chinese medicine does not have addiction property, uncertain therapeutic efficacy is cut, and the curative effect fluctuation range is big.Therefore, still need determined curative effect in this area, do not have addicted anti-additive medicament.
Sumatriptan is at present clinically as the migrainous drug use of treatment; Be used for the adult tendency or the migrainous acute attack of absence of aura are arranged; " Sumatriptan Succinate oral formulations description " referring to State Food and Drug Administration's promulgation; State food medicine prison is annotated [2010] No. 200, in full by reference in this paper as a reference.The chemical name of Sumatriptan Succinate is 3-[2-(dimethylamino) ethyl]-N-methylindole-5-NSC-249992 succinate.Its chemical structural formula is following:
The unexpected discovery of the inventor, sumatriptan have the effect of stronger inhibition morphine abstinence syndrome symptom, and do not have addiction property, can be used as anti-additive medicament and are used to prevent and treat the opioid dependent symptoms.
Summary of the invention
The present invention provides sumatriptan or the application of its pharmaceutically acceptable salt in the medicine of preparation prevention or treatment opioid dependent symptoms.The preferred Sumatriptan Succinate of the pharmaceutically acceptable salt of sumatriptan wherein.
The present invention also provides the application of the preparation that comprises sumatriptan or its pharmaceutically acceptable salt in the medicine of preparation prevention or treatment opioid dependent symptoms.Said preparation is for comprising sumatriptan or its pharmaceutically acceptable salt, by the preparation of conventional dose technology preparation, like powder spray, aerosol, oral liquid, tablet, capsule, injection, patch.Wherein preferred powder spray, aerosol.
Beneficial effect (comparison of giving up active and existing anti-additive medicament of Sumatriptan Succinate)
One. material
1. laboratory animal
Male mice in kunming, body weight 18-22g is provided by Zhongshan University's Experimental Animal Center.
2. trial drug
The morphine sulfate injection, Qinghai Pharmaceutic Plant produces, lot number: 2010051209;
Naloxone hydrochloride injection, Fourth Ring, Beijing pharmaceutical factory produces, lot number: 10082205;
Clonidine hydrochloride, sky, Suizhou, Hubei medical sci-tech company provides lot number: 10021113.
Two. method
1. administration
Reference literature model (Gen Pharmacol, 1994,25 (7): 1505-1510), adopt the subcutaneous injection incremental method to set up morphine and rely on model.Male Kunming strain mice, 8 every group.On-test, respectively organized the subcutaneous injection morphine sulfate, every day 3 times, continuous 7 days.Starting dose is 5mg/kg, and double later every day, reaches 160mg/kg by the 6th day, is maintained to the 7th day.After the last administration 2.5 hours, each was organized under the mouse peritoneum administration or gives normal saline, and each mouse peritoneum injected naloxone 4.5mg/kg observes mouse jump number of times in 15 minutes immediately after 30 minutes.The result sees table 1:
The comparison of table 1 Sumatriptan Succinate and clonidine inhibition morphine-dependent mice withdrawal symptom (n=10, x ± s)
Compare * P＜0.05, * * P＜0.01 with morphine dependence group; Compare #P＞0.05 with clonidine
2. date processing
(x ± s) expression carries out statistical procedures with student t check to data with mean ± standard deviation.
The result draws by table 1: high, medium and low dose groups Sumatriptan Succinate is compared mice with morphine dependence group withdrawal symptom exists significantly or extremely remarkable significant difference; High, medium and low dose groups Sumatriptan Succinate is compared no remarkable significant difference with clonidine group, prove that Sumatriptan Succinate can be used as anti-additive medicament and uses.The result proves that Sumatriptan Succinate has prevention that obviously is superior to prior art and the effect of treating the opioid dependent symptoms, can be used as anti-additive medicament and uses.
The specific embodiment
Further specify technical scheme of the present invention through specific embodiment below, these embodiment only are described further and replenish the present invention, the invention is not restricted to these embodiment.
Embodiment 1
The preparation of sumatriptan powder spray
Sumatriptan Succinate 40g
Lactose 960g
Process 1000
Get Sumatriptan Succinate and cross 200 mesh sieves,, cross 200 mesh sieves, two batches of fine powders through 200 mesh sieves are merged not pulverizing with jet mill through the macroparticle of sieve, subsequent use; Get lactose and prepare the lactose fine powder as stated above; Take by weighing subsequent use Sumatriptan Succinate, the lactose of recipe quantity respectively, stir down, in batches, alternately add the V-type mixing channel, mix homogeneously is pressed 1g powder/grain, and filled capsules promptly gets the sumatriptan powder spray, passes through special-purpose doser per nasal inhalation during use.
Embodiment 2
The preparation of sumatriptan aerosol
Sumatriptan Succinate 20g
Potassium sorbate is an amount of
Deionized water is an amount of
Process 1000ml
Get the recipe quantity Sumatriptan Succinate, add the appropriate amount of deionized water dissolving, add an amount of potassium sorbate dissolving again, stir; Filter, filtrating adds deionized water to 1000ml, presses the 20ml/ bottle, adds pressure vessel; Container is airtight, charge into tetrafluoroethane, promptly get the sumatriptan aerosol.
Claims (5)
1. sumatriptan or its pharmaceutically acceptable salt application in the medicine of preparation prevention or treatment opioid dependent symptoms.
2. purposes as claimed in claim 1, wherein the pharmaceutically acceptable salt of sumatriptan is a Sumatriptan Succinate.
3. comprise the application of preparation in the medicine of preparation prevention or treatment opioid dependent symptoms of sumatriptan or its pharmaceutically acceptable salt.
4. purposes as claimed in claim 3, wherein said preparation are powder spray, aerosol, tablet, capsule, injection, oral liquid, patch.
5. purposes as claimed in claim 3, wherein said preparation is preferably powder spray or aerosol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110457284 CN102488684B (en) | 2011-12-30 | 2011-12-30 | Application of sumatriptan in preparation of medicines for preventing and treating narcomania |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110457284 CN102488684B (en) | 2011-12-30 | 2011-12-30 | Application of sumatriptan in preparation of medicines for preventing and treating narcomania |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102488684A true CN102488684A (en) | 2012-06-13 |
| CN102488684B CN102488684B (en) | 2013-08-28 |
Family
ID=46180591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110457284 Expired - Fee Related CN102488684B (en) | 2011-12-30 | 2011-12-30 | Application of sumatriptan in preparation of medicines for preventing and treating narcomania |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102488684B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101134025A (en) * | 2007-10-10 | 2008-03-05 | 南昌弘益科技有限公司 | Hydrochloric acid flunarizine dropping pills |
-
2011
- 2011-12-30 CN CN 201110457284 patent/CN102488684B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101134025A (en) * | 2007-10-10 | 2008-03-05 | 南昌弘益科技有限公司 | Hydrochloric acid flunarizine dropping pills |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102488684B (en) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2755638B1 (en) | Tamper resistant immediate release formulations | |
| KR101630467B1 (en) | Inhibitor of analgesic tolerance | |
| MX2010011727A (en) | Oral administration of peripherally-acting opioid antagonists. | |
| EP2574167A2 (en) | Liquid nasal spray containing low-dose naltrexone | |
| CN1081034C (en) | Medicine of diguanidino-prine-hydride compounds for giving up drug-taking | |
| KR20140019445A (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN102488684B (en) | Application of sumatriptan in preparation of medicines for preventing and treating narcomania | |
| CN102038706A (en) | Drug treatment and rehabilitation Chinese herbal composition | |
| CN103223080B (en) | Traditional Chinese medicinal composition for tranquilizing mind by nourishing the heart and preparation method thereof | |
| CN106237333A (en) | The medical usage of corydalmine | |
| CN107951940B (en) | Blood pressure lowering medicine composition | |
| CN102641252A (en) | Terbinafine hydrochloride solid dispersoid and tablet thereof | |
| CN109077352A (en) | A kind of addiction and heroinomania product | |
| CN102106854A (en) | Application of sinomenine to preparation of analgesic drug | |
| CN102204976A (en) | Pummelo peel extract with hypoglycemic activity and preparation method thereof | |
| CN106176740B (en) | The medical usage of the anti-habituation of corydalmine | |
| CN101513431A (en) | Omphalia preparation and preparation method | |
| CN102380088A (en) | Prescription and preparation method of thymopeptide-5 injection | |
| CN110882247A (en) | Use of isorhynchophylline in preparing drug-relief medicine | |
| CN104523772A (en) | Abelmoschl manihot L medic total alkaloid extract, preparation method and applications thereof | |
| US20140275138A1 (en) | Method and products for treating diabetes | |
| CN100423779C (en) | Medicinal composition comprising active components of 5-HT 3 receptor antagonist and H2 receptor antagonist and use thereof | |
| CN100556436C (en) | Dependent drug-breaking medicine of a kind of anti-opiates and preparation method thereof | |
| TW200840591A (en) | The applications of Cucurbitacins in increasing the number of white blood cells | |
| CN1332664C (en) | Snuff |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130828 Termination date: 20171230 |